Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perinatal thrombocytopenia

R F Burrows1, J G Kelton

  • 1Department of Obstetrics and Gynecology, McMaster University Medical Centre, Hamilton, Ontario, Canada.

Clinics in Perinatology
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Journal of thrombosis and haemostasis : JTH·2014
Same author

FcγRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2013
Same author

A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2012
Same author

A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins.

Journal of thrombosis and haemostasis : JTH·2012

Maternal thrombocytopenia during pregnancy rarely predicts fetal thrombocytopenia. Alloimmune thrombocytopenia poses the true risk to newborns, but identifying cases and managing future pregnancies remains challenging.

Area of Science:

  • Obstetrics and Gynecology
  • Neonatal Medicine
  • Immunology

Background:

  • Thrombocytopenia, a low platelet count, is frequently observed in pregnant individuals.
  • Existing maternal platelet counts are unreliable indicators of fetal platelet levels, even in pathological cases.

Purpose of the Study:

  • To highlight the significant risk of alloimmune thrombocytopenia to the fetus and neonate.
  • To underscore the diagnostic and management challenges associated with alloimmune thrombocytopenia in pregnancy.

Main Methods:

  • Review of existing literature on maternal and fetal thrombocytopenia.
  • Analysis of diagnostic criteria and management strategies for alloimmune thrombocytopenia.

Main Results:

Related Experiment Videos

  • Maternal thrombocytopenia is a poor predictor of fetal thrombocytopenia.
  • Alloimmune thrombocytopenia represents the primary thrombotic risk to neonates.

    • Conclusions:

    • Accurate identification of alloimmune thrombocytopenia cases is crucial.
    • Standardized management protocols for future pregnancies affected by alloimmune thrombocytopenia are needed.